Indobufen is a new generation of anti-platelet aggregation
drug, but studies were not sufficient on its
anticoagulant effects. In the present study, the
anticoagulant activity of
indobufen was determined by monitoring the activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) in rabbit plasma. We evaluated the
anticoagulant mechanisms on the content of the platelet factor 3,4 (PF3,4), and the
coagulation factor 1, 2, 5, 8, 10 (FI, II, V, VIII, X) in rabbits, as well as the in vivo bleeding time and clotting time in mice. The pharmacodynamic differences between
indobufen and
warfarin sodium,
rivaroxaban, and
dabigatran were further studied on
thrombus formation and the content of FII and FX in rats. Animal experiments showed that intragastric-administrated
indobufen can significantly reduce the APTT, PT, TT, PF3, FI, II, V, VIII, and X plasma contents. Its inhibitory effect on plasma FII was better than
thrombin inhibitor
dabigatran with effect on FX better than FXa inhibitor
rivaroxaban. These results suggest that
indobufen has some
anticoagulant effects as strong as some conventional
anticoagulants. The mechanism may be related to both exogenous and endogenous coagulation system.